Establishment of health clinics as mass screening and referral systems for chronic non-communicable diseases in primary health care

International Journal of Preventive Medicine

Volumn 3, Issue 3, 2012, Pages 173-180

  Heidari, Kamal ^a   Sajjadi, Sayyed Ali ^a   Hadian, Rezvaneh ^a   Hadi, Somayeh ^a   Hosseinkhani, Ramesh ^a   Amini, Soudabeh ^a   Kiani, Zahra ^a   Ajami, Ali ^a   Fadaei, Reza ^a   Shahriari, Anahita ^a   Keramatian, Kasra ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes; Metabolic syndrome; Prevention; Screening

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEALTH CENTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INFANT; IRAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PREGNANCY DIABETES MELLITUS; PRESCHOOL CHILD; PREVALENCE; PRIMARY HEALTH CARE; RISK FACTOR; SCHOOL CHILD; SCREENING TEST;

EID: 84858590105     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Diabetes Key Facts. WHO Media centre; January 2011. Available from: http: // www.who.int/mediacentre/ factsheets/fs312/en/index.html [Last cited on 2011 Jun 11]
2. Rathmann W, Giani G. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:2568-9.
3. Yang SH, Dou KF, Song WJ. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:2425-6.
4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
5. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008;31 Suppl 1:S12-54.
6. Harris MI. Undiagnosed NIDDM: Clinical and public health issues. Diabetes Care 1993;16:642-52.
7. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992;15:815-9.
8. Thompson TJ, Engelgau MM, Hegazy M, Ali MA, Sous ES, Badran A, et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med 1996;13:337-40.
9. Klein R, Klein BE, Moss S, DeMets DL. Proteinuria in diabetes. Arch Intern Med 1988;148:181-6.
10. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293-301.
11. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, et al. Age at initiation and frequency of screening to detect type 2 diabetes: A cost-effectiveness analysis. Lancet 2010;375:1365-74.
12. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, et al. Different strategies for screening and prevention of type 2 diabetes in adults: Cost effectiveness analysis. BMJ 2008;336:1180-5.
13. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: A cost-effectiveness analysis. Ann Intern Med 2004;140:689-99.
14. Kelishadi R, Alikhani S, Delavari A, Alaedini F, Safaie A, Hojatzadeh E. Obesity and associated lifestyle behaviours in Iran: findings from the First National Non-communicable Disease Risk Factor Surveillance Survey. Public Health Nutr 2008;11:246-51.
15. Delavari A, Forouzanfar MH, Alikhani S, Sharifian A, Kelishadi R. First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: the national survey of risk factors for noncommunicable diseases of Iran. Diabetes Care 2009;32:1092-7.
16. Esteghamati A, Meysamie A, Khalilzadeh O, Rashidi A, Haghazali M, Asgari F, et al. Third national Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) in Iran: Methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health 2009;9:167.
17. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 1969;22:158-61.
18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32 Suppl 1:S62-7.
19. World Health Organ Tech Rep Ser. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. 2000;894:i-xii, 1-253.
20. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 2005;13:322-7.
21. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
22. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
23. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263-8.
24. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002;25:829-34.
25. Kim SM, Lee JS, Lee J, Na JK, Han JH, Yoon DK, et al. Prevalence of diabetes and impaired fasting glucose in Korea: Korean National Health and Nutrition Survey 2001. Diabetes Care 2006;29:226-31.
26. Gu D, Reynolds K, Duan X, Xin X, Chen J, Wu X, et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia 2003;46:1190-8.
27. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001;44:1094-101.
28. Onat A, Hergenc G, Uyarel H, Can G, Ozhan H. Prevalence, incidence, predictors and outcome of type 2 diabetes in Turkey. Anadolu Kardiyol Derg 2006;6: 314-21.
29. Al-Moosa S, Allin S, Jemiai N, Al-Lawati J, Mossialos E. Diabetes and urbanization in the Omani population: An analysis of national survey data. Popul Health Metr 2006;4:5.
30. al-Mahroos F, McKeigue PM. High prevalence of diabetes in Bahrainis. Associations with ethnicity and raised plasma cholesterol. Diabetes Care 1998;21:936-42.
31. Azizi F, Guoya MM, Vazirian P, Dolatshati P, Habbibian S. Screening for type 2 diabetes in the Iranian national programme: A preliminary report. East Mediterr Health J 2003;9:1122-7.
32. Sadeghi M, Roohafza H, Shirani S, Poormoghadas M, Kelishadi R, Baghaii A, et al. Diabetes and associated cardiovascular risk factors in Iran: The Isfahan Healthy Heart Programme. Ann Acad Med Singapore 2007;36:175-80.
33. Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaedini F, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National Survey of Risk Factors for Non-Communicable Diseases of Iran. Diabetes Care 2008;31:96-8.
34. Azimi-Nezhad M, Ghayour-Mobarhan M, Parizadeh MR, Safarian M, Esmaeili H, Parizadeh SM, et al. Prevalence of type 2 diabetes mellitus in Iran and its relationship with gender, urbanisation, education, marital status and occupation. Singapore Med J 2008;49:571-6.
35. Zimmet P. Epidemiology of diabetes mellitus and associated cardiovascular risk factors: Focus on human immunodeficiency virus and psychiatric disorders. Am J Med 2005;118 Suppl 2:3S-8S.
36. Passos VM, Barreto SM, Diniz LM, Lima-Costa MF. Type 2 diabetes: Prevalence and associated factors in a Brazilian community--the Bambui health and aging study. Sao Paulo Med J 2005;123:66-71.
37. Rosenthal M, Haskell WL, Solomon R, Widstrom A, Reaven GM. Demonstration of a relationship between level of physical training and insulin-stimulated glucose utilization in normal humans. Diabetes 1983;32:408-11.
38. Mayer-Davis EJ, D'Agostino R, Jr., Karter AJ, Haffner SM, Rewers MJ, Saad M, et al. Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study. JAMA 1998;279:669-74.
39. Cheng KC, Chen YL, Lai SW. Prevalence of dyslipidemia in patients receiving health checkups: a hospital-based study. Cholesterol 2011;2011:314234.
40. Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine 2008;34:36-51.
41. Sonkodi B, Sonkodi S, Steiner S, Helis E, Turton P, Zachar P, et al. High prevalence of prehypertension and hypertension in a working population in Hungary. Am J Hypertens 2012;25:204-8.
42. Erem C, Hacihasanoglu A, Kocak M, Deger O, Topbas M. Prevalence of prehypertension and hypertension and associated risk factors among Turkish adults: Trabzon Hypertension Study. J Public Health (Oxf) 2009;31:47-58.
43. Velazquez Monroy O, Rosas Peralta M, Lara Esqueda A, Pastelin Hernandez G, Attie F, Tapia Conyer R, et al. Arterial hypertension in Mexico: Results of the National Health Survey 2000. Arch Cardiol Mex 2002;72:71-84.
44. Lara A, Rosas M, Pastelin G, Aguilar C, Attie F, Velazquez Monroy O. Hypercholesterolemia and hypertension in Mexico: Urban conjunctive consolidation with obesity, diabetes and smoking. Arch Cardiol Mex 2004;74:231-45.
45. Rodriguez Bernardino A, Garcia Polavieja P, Reviriego Fernandez J, Serrano Rios M. Prevalence of metabolic syndrome and consistency in its diagnosis in type 2 diabetic patients in Spain. Endocrinol Nutr 2010;57:60-70.
46. Athyros VG, Ganotakis ES, Elisaf MS, Liberopoulos EN, Goudevenos IA, Karagiannis A, et al. Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol 2007;117:204-10.
47. Cho LW. Metabolic syndrome. Singapore Med J 2011;52:779-85.
48. Jordan HT, Tabaei BP, Nash D, Angell SY, Chamany S, Kerker B. Metabolic syndrome among adults in New York city, 2004 New York city health and nutrition examination survey. Prev Chronic Dis 2012;9:E04.
49. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
50. Al-Lawati JA, Mohammed AJ, Al-Hinai HQ, Jousilahti P. Prevalence of the metabolic syndrome among Omaniadults. Diabetes Care 2003;26:1781-5.
51. Ozsahin AK, Gokcel A, Sezgin N, Akbaba M, Gzuvener N, Ozisik L, et al. Prevalence of the metabolic syndrome in a Turkish adult population. Diabetes Nutr Metab 2004;17:230-4.
52. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.